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Abstract
The objective of the research was to investigate the content of insulin, insulin-like growth factor-1 and phos-
phorylated protein kinase proline-rich Akt substrate of 40kDa and to determine their role in the activation of
oncogenesis processes in women with type 2 diabetes mellitus and endometrial cancer.
Materials and methods. There were examined 46 women who were divided into 4 groups: Group I included
healthy women; Group II comprised women with type 2 diabetes mellitus; Group III included women with
endometrial cancer; Group IV comprised women with endometrial cancer and co-existent type 2 diabetes
mellitus. The levels of insulin, insulin-like growth factor-1, phosphoproline-rich Akt substrate of 40kDa were
determined by immune-enzyme analysis. The compensation of diabetes mellitus was evaluated by hemoglobin
A1c level using method of ion-exchange chromatography. The results obtained were analyzed using statistical
analysis.
Results. Women of all study groups had increased levels of insulin and insulin-like growth factor-1 as compared
to the control group (p<0.05). The level of phospho-proline-rich Akt substrate of 40kDa increased in the patients
of Group II (p<0.05) and the patients of Group III (p<0.05) and decreased in the patients of Group IV (p<0.05).
According to correlation analysis, phospho-proline-rich Akt substrate of 40kDa was found to correlate with body
mass index, insulin and insulin-like growth factor-1 in Group II, body mass index and insulin-like growth factor-1
in Group III and body mass index in Group IV (p<0.05).
Conclusions. There was found an association between type 2 diabetes mellitus and endometrial cancer through
obesity, hyperinsulinemia and insulin-like growth factor-1. The increase in phospho- proline-rich Akt substrate of
40kDa level was a sign of activation of mTOR and oncogenesis processes in the patients with type 2 diabetes
mellitus. The decrease in phospho-proline-rich Akt substrate of 40kDa in the patients with endometrial cancer
and co-existent type 2 diabetes mellitus can be explained by the influence of other intracellular regulatory systems
or the effects of antidiabetic drugs, that requires additional study.
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Problem statement and analysis of
the latest research
According to the recent research, there is an in-
creased risk of cancer in the patients with diabetes
mellitus (DM), including pancreatic, liver, intestine,
breast, urinary tract and endometrial cancers [11,
16]. Data on prostate cancer are ambiguous [15].
Endometrial cancer (EC) is one of the most com-
mon cancer localizations in women during meno-
pause. There are two types of EC: the first type
(estrogen-dependent) is associated with the effect
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Figure 1. Mechanisms of activation of oncogenesis in patients with T2DM: IGF-1 – insulin-like growth
factor-1; Akt – alpha serine/threonine-protein kinase B; RAS – membrane-bound proteins, which are
involved in signal transduction; RAF – proteins, components of MAPK kinase; ROS – reactive oxygen
species; LKB1 – liver kinase B1; AMPK – adenosine monophosphate-activated protein kinase; TSC2 –
tuberous sclerosis complex 2.
of hyperestrogenemia in women with endocrine and
metabolic disorders (obesity, DM, hypertension)
and is observed in 70% of cases, while the sec-
ond type, autonomous (non-estrogen-dependent),
is found in less than 30% of the patients, occuring
on the background of endometrial atrophy in case
of the absence of hyperestrogenism and metabolic
disorders.
The common pathogenetic mechanisms of de-
veloping type 2 DM (T2DM) and reproductive can-
cer are obesity, chronic inflammation and cytokine
imbalance, hyperinsulinemia and insulin resistance
(IR), hyperglycemia and oxidative stress (OS) [12].
These factors cause pathological changes at the in-
tracellular level, thereby initiating the processes of
proliferation and inhibition of apoptosis [5].
Hyperinsulinemia and high levels of IGF acti-
vate tyrosine kinase of the insulin receptor substrate
(IRS), leading to signal transduction via the intracel-
lular signaling pathways: the RAS/RAF/ mitogen-
activated protein kinase (MAPK) and phosphatidyli-
nositol 3-kinase (PI3K) /Akt/mTOR (Fig. 1).
PI3K/Akt/mTOR is one of many signaling path-
ways that are typical for most human cells. It me-
diates the main effects of insulin in cells, namely
stimulates the synthesis of protein, glycogen, lipids,
suppresses gluconeogenesis, lipolysis, and regu-
lates key aspects of cancer, including cell growth
and survival. Being influenced by insulin, PI3K
activates the serine/threonine protein kinase cas-
cade, which includes phosphoinositide-dependent
kinase-1 (PDK-1), the substrate of which is the Akt
of the protein kinase B family. Akt is a key en-
zyme for signal trasmission along this path; more-
over, it is involved in the regulation of glycemia
level by influencing glycogen synthesis and translo-
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cation of the main glucose transporter - glucose
transporter type 4 (GLUT-4). In many malignant
diseases, Akt acts as oncogene due to the phos-
phorylation of substrates, including the mammalian
target of rapamycin (mTOR) [8]. mTOR includes
two complexes: mTOR complex 1 (mTORC1) and
mTOR complex 2 (mTORC2). Raptor and proline-
rich Akt substrate of 40kDa (PRAS40) are specific
for mTORC1, while Rictor, mitogen-activated pro-
tein kinase-associated protein 1 (mSin1) and Protor-
1/2 are specific for mTORC2. These complexes
interact with different substrates and initiate dif-
ferent signaling paths. The mTOR regulates the
processes of apoptosis, cell proliferation and cell
survival (Fig. 1).
PRAS40 is a substrate of Akt-1 (Akt1S) in the
signaling cascade PI3K/Akt/mTORC1. It is part
of mTORC1 and is its negative regulator. Phos-
phorylation of PRAS40 leads to the dissociation of
PRAS40 from Raptor in the mTOR complex that
facilitates the activation of mTOR. PRAS40 and
mTOR are involved in regulating cell sensitivity to
insulin. Increased level of phospho-PRAS40 was
found identified in several types of tumors, includ-
ing endometrial, cervical and ovarian ones. Thus,
this protein kinase can serve as a potential target
during the treatment of various types of cancer [17].
The pathogenetic factors of DM contribute to
the dysfunction of intracellular regulatory systems,
namely the PI3K/Akt/mTOR signaling pathway,
which is now considered as one of the therapeutic
goals of molecular-directed cancer treatment [1].
The objective of the research was to investi-
gate the content of insulin, IGF-1 and phospho-
PRAS40 and to determine their role in the activation
of oncogenesis processes in women with T2DM and
EC.
1. Materials and Methods
There were examined 46 women. All the patients
were divided into 4 groups: Group I included healthy
women; Group II comprised women with T2DM;
Group III included women with EC; Group IV com-
prised women with EC and co-existent T2DM. The
groups of patients were homogeneous by age, and
severity of the disease. Antidiabetic therapy (ADT)
for the patients with DM included various com-
binations of tablets and insulin. All the patients
signed an informed consent for further diagnos-
tic and research work. The content of phospho-
PRAS40, levels of insulin and IGF-1 were deter-
mined by immune-enzyme assay using diagnostic
reagents human PRAS40 [pT246], Enzyme Linked
Immunosorbent Assay (ELISA) kit KHO0421 (In-
vitrogen, USA), Insulin ELISA EIA-2935 (DRG,
Germany) and IGF-1 600 ELISA EIA-4140 (DRG,
Germany). Hemoglobin A1c (HbA1c) was deter-
mined by ion exchange chromatography, using di-
agnostic reagents Bio-Rad (USA).
The analysis of the data was carried out us-
ing Statistica 12.0 (StatSoft Inc., USA), One-Way
ANOVA program. The data are presented as x± SD
(x ± standard deviation). The differences between
the values in the control and experimental groups
were determined using the Student’s t-test. The
values of p < 0.05 were considered as significant.
2. Results and Discussion
The analysis of the anthropometric data indicated
the tendency of women with EC to obesity; BMI
was > 30 kg/m2. Age-related characteristics con-
firmed the prevalence of EC in women in the post-
menopausal period. HbA1c levels in Group II and
Group IV were higher than 8.0%, indicating DM
decompensation. Hyperinsulinemia was found in
the patients with DM of both groups (p<0.05) and
in women of Group III (p<0.05). Significantly
higher level of IGF-1, as compared to the con-
trol group, was found in the patients of all groups
(p<0.05). Significantly higher content of phospho-
PRAS40 was detected in Group II and Group III
(p<0.05), while in Group IV, it decreased signifi-
cantly (p<0.05) (Table 1).
The elevated insulin levels in all study groups
confirmed insulin resistance in the patients with
T2DM, as well as in the patients with obesity. Ex-
cessive synthesis of insulin decreased the produc-
tion of IGF-binding proteins 1, 2 (IGFBP1, 2) in
the liver and promoted IGF bioavailability.
In addition, hyperinsulinemia led to decrease
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Table 1. Levels of insulin, IGF-1, phospho-PRAS40 in the patients with T2DM and EC.
Indicator
Group I Group II, Group III, Group IV,
(the control
group),
DM type 2, EC, DM type 2+EC,
n=10 n=12 n=12 n=12
Age, (years) 58.91 ± 8.96 55.23 ± 6.19 62.25 ± 2.45 61.58 ± 6.91
BMI, (kg/m2) 29.17 ± 3.75 32.10 ± 3.68 33.86 ± 3.70 31.84 ± 6.19
Insulin, (mIU/ml) 7.1 ± 2.4 27.2 ± 11.1* 11.8 ± 2.1*/** 17.5 ± 11.7*/**
IGF-1, (ng/ml) 141.3 ± 28.9 177.9 ± 29.9*/# 481.9 ± 292.4 * 183.3 ± 37.7*/#
ph-PRAS40, U/ml 1.148 ± 0.101 1.744 ± 0.459 * 1.809 ± 0.591 * 0.131 ± 0.014 *
Notes:
* - the difference from the control group is significant, p<0.05;
** - the difference from the Group II is significant, p<0.05;
# - the difference from the Group III is significant, p<0.05.
in the synthesis of sex hormone-binding globulin
(SHBG) in the liver, thereby increasing the levels
of free estrogen. SHBG has been identified as an
indicator of an increased risk of EC [9, 12].
The elevated level of IGF-1 in Group III indi-
cated the additional mechanisms for stimulating its
synthesis during EC, not only by hyperinsulinemia.
The increase in the level of this growth hormone
may be due to the effects of obesity and cytokine
imbalance. The obesity impact on the risk of re-
productive cancer is caused by active conversion
of androgens to estradiol in peripheral adipose tis-
sue, as well as through the state of chronic inflam-
mation and cytokine imbalance. Proinflammatory
cytokines (interleukin-6 (IL-6) and tumor necrosis
factor-α (TNF-α)) have pro-cancerogenic effects in
case of the excess, activating the PI3K/Akt/mTOR
signaling pathway of cell proliferation. Overexpres-
sion of leptin in cancerous ovarian tissues is recog-
nized as the marker of aggressive malignancy. In
contrast, adiponectin (APN) has a direct inhibitory
effect on tumor cells [10, 14].
Hyperestrogenic effects can be involved in this
type of cancer, since estradiol stimulates local syn-
thesis of IGF in endometrial tissue [10, 14].
The reduced level of IGF-1 in the patients of
Group II and Group IV with T2DM in compari-
son with those in Group III may be attributed to
the positive pleiotropic effects of metformin, which
was used in the treatment of most patients; that co-
incided with the results of other scientific studies
on the ability of this drug to affect pathogenetic
”diabetes-induced” mechanisms of cancer, includ-
ing the level of IGF-1 [2, 4]. Other research ex-
plained the increase in IGF-1 levels through insulin
resistance in the patients with T2DM and the bind-
ing of IGF-2 to IGF-1 receptor [7]. The study car-
ried out by Dai C et al., did not show a significant
difference between the levels of IGF-1 in the pa-
tients who had both T2DM and EC and in those,
who had EC only. However, there was detected
the activation of receptors to IGF-2 in endometrial
cancer cells, which explains the activation of PI3K
due to the loss of competitive binding of IGF-2 to
receptors of IGF-1 [6].
The increase in the content of phospho-PRAS40
in the patients of Group II and Group III indicated
the activation of the PI3K/Akt/mTOR signaling
pathway through the pathogenetic mechanisms of
cancer and T2DM, including obesity, hyperinsulin-
ism and increase in IGF-1 level.
The decrease in phospho-PRAS40 level in women
with EC secondary to T2DM can be explained by
the influence of other intracellular regulators, namely
the activation of AMPK. A co-existence of DM and
cancer associated with severe chronic stress, en-
ergy deficit, activating the tumor suppressor LKB1
and AMPK, promotes the phosphorylation of TSC2
that leads to suppressing the mTOR signaling path-
way [3, 13]. On the other hand, the decreased level
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of phospho-PRAS40 may be explained by the influ-
ence of ADT or due to the competition of protein
kinases of various signaling pathways for common
substrates, which requires additional study.
In women of Group II with T2DM, phospho-
PRAS40 correlated with BMI (r=0.57, p<0.05), in-
sulin (r=0.56, p<0.05) and IGF-1 (r=0.48, p<0.05).
In women of Group III, phospho-PRAS40 corre-
lated with BMI (r=0.42, p<0.05) and IGF-1 (r=0.45,
p<0.05). In women of Group IV, phospho-PRAS40
correlated with BMI (r=0.50, p<0.05) only.
The dependence of phospho-PRAS40 content
on the level of insulin and IGF-1 in the patients
with T2DM proved the important influence of these
growth factors on the oncogenesis processes. No
significant effect of hyperglycemia on the activ-
ity of phospho-PRAS40 was detected. However,
most patients of Group IV had decompensated dia-
betes, which certainly contributes to carcinogenesis.
Chronic hyperglycemia and pathological pathways
of glucose transformation lead to OS, the accumu-
lation of ROS, which contributes to the oxidation
of intracellular structures (proteins, lipids, DNA)
and causes their mutations and dysfunction. OS
activates the ROS/MAPK signaling pathway, that
controls gene transcription, metabolism, as well as
proliferation, apoptosis and cell survival (Fig. 1).
The determination of the level of phospho-
PRAS40 provides an opportunity to evaluate the
activity of the PI3K/Akt/mTOR signaling pathway
in the patients with T2DM and cancer. For a practic-
ing endocrinologist, the relevance of achieving DM
compensation, correcting hyperinsulinemia and nor-
malizing IGF-1 level in order to prevent the dysreg-
ulation of intracellular systems being involved in
processes of carcinogenesis are confirmed
3. Conclusions
There was found an association between T2DM and
EC through obesity, hyperinsulinemia and activa-
tion of IGF-1. The increase in the level of phospho-
PRAS40 was a sign of activating mTOR and onco-
genesis processes in the patients with T2DM. The
decrease in phospho-PRAS40 in the patients with
EC and co-existent T2DM can be explained by the
influence of other intracellular regulatory systems
or the effects of antidiabetic drugs, that requires
additional study.
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